# Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial

> **NCT06825208** · — · NOT_YET_RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 29 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage
- ELDERLY PEOPLE

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06825208
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825208, "Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06825208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*